Clinical Trial Update: Design and Validation of a Generative AI and Propensity Score Matching Model for the VEN-DEC Phase II Study in Elderly AML Eligible for Allo-SCT; Evaluation of an Exploratory Approach Respect to a Randomized Phase III Trial

View source ↗

Summary

A trial-design study describing a Generative AI and propensity-score matching model for the VEN-DEC Phase II AML study in elderly patients eligible for allogene…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Decitabine (Decitabine)
• Venetoclax (venetoclax)

Snippet

Sponsor: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | Conditions: Acute Myeloid Leukemia | Status: NOT_YET_RECRUITING